The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“; in the basolateral amygdala after retrieval of an unpleasant memor”
Self-citationFormation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Self-citationA second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 1×
“and recently shown to control 2-AG levels in isolated cells ( Box 1”
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208
Self-citationCota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thöne-Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039
Self-citationHuang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122196999 · Cited by 964
Self-citationZajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners
Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T., & Ueda, N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306642200 · Cited by 805
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
Self-citation2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor
Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., & Mechoulam, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061029898 · Cited by 762
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
Self-citationSR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Galve-Roperh, I., Sánchez, C., Cortés, M. L., del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000) · Nature Medicine · doi:10.1038/73171 · Cited by 682
Modulation of transmitter release via presynaptic cannabinoid receptors
Schlicker, E., & Kathmann, M. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01805-8 · Cited by 671
Heterosynaptic LTD of Hippocampal GABAergic Synapses
Chevaleyre, V., & Castillo, P. E. (2003) · Neuron · doi:10.1016/s0896-6273(03)00235-6 · Cited by 655
Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.-H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., & Mechoulam, R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00392-6 · Cited by 629
Self-citationBenito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 624
Porter, A. C., Sauer, J.-M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1020 · Cited by 615
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., & Soubrié, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802583 · Cited by 583
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanuš, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 571
Cannabis: pharmacology and toxicology in animals and humans
ADAMS, I. B., & MARTIN, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 570
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrié, P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00545.2002 · Cited by 566
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 532
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491
Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling
Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C., & Cravatt, B. F. (2002) · Science · doi:10.1126/science.1076535 · Cited by 490
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez, C., CEBALLOS, M. L. D., del Pulgar, T. G., Rueda, D., Corbacho, C., Velasco, G., Galve‐Roperh, I., Huffman, J. W., y Cajal, S. R., & Guzmán, M. (2001) · Cancer Research · Cited by 489
Pharmacology of Cannabinoid Receptors
Howlett, A. C. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.003135 · Cited by 488
Pain modulation by release of the endogenous cannabinoid anandamide
Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K., & Sañudo-Peña, M. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12198 · Cited by 485
It could be habit forming: drugs of abuse and striatal synaptic plasticity
Gerdeman, G. L., Partridge, J. G., Lupica, C. R., & Lovinger, D. M. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00065-1 · Cited by 480
The endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
Self-citationThe endogenous cannabinoid system protects against colonic inflammation
Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., & Lutz, B. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19465 · Cited by 460
Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
Casanova, M., Blázquez, C., Martínez‐Palacio, J., Villanueva, C., Fernández‐Aceñero, M. J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16116 · Cited by 437
cDNA Cloning, Tissue Distribution, and Identification of the Catalytic Triad of Monoglyceride Lipase
Karlsson, M., Contreras, J. A., Hellman, U., Tornqvist, H., & Holm, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27218 · Cited by 422
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., & Di Marzo, V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8375 · Cited by 413
Self-citationNon-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study
GRANT, I., GONZALEZ, R., CAREY, C. L., NATARAJAN, L., & WOLFSON, T. (2003) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617703950016 · Cited by 411
Varga, K., Wagner, J. A., Bridgen, D. T., & Kunos, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.11.1035 · Cited by 410
Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702351 · Cited by 404
Cadas, H., di Tomaso, E., & Piomelli, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01226.1997 · Cited by 396
The endogenous cannabinoid system protects against colonic inflammation
Massa, F., Marsicano, G., Hermann, H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419465 · Cited by 387
Discovering potent and selective reversible inhibitors of enzymes in complex proteomes
Leung, D., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2003) · Nature Biotechnology · doi:10.1038/nbt826 · Cited by 385
Bátkai, S., Járai, Z., Wagner, J. A., Goparaju, S. K., Varga, K., Liu, J., Wang, L., Mirshahi, F., Khanolkar, A. D., Makriyannis, A., et al. (2001) · Nature Medicine · doi:10.1038/89953 · Cited by 378
Endocannabinoids control spasticity in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0399fje · Cited by 378
Self-citationBiosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes
Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L., & Di Marzo, V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3315 · Cited by 369
Self-citationInhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
Casanova, M., Blázquez, C., Martínez‐Palacio, J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316116 · Cited by 359
A missense mutation in human fatty acid amide hydrolase associated with problem drug use
Sipe, J. C., Chiang, K., Gerber, A. L., Beutler, E., & Cravatt, B. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082235799 · Cited by 355
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology · doi:10.1212/wnl.57.11.2108 · Cited by 349
The endogenous cannabinoid system and brain development
Fernández-Ruiz, J., Berrendero, F., Hernández, M. L., & Ramos, J. A. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01491-5 · Cited by 347
Egertová, M., Cravatt, B. F., & Elphick, M. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00145-3 · Cited by 347
Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
Hillard, C. J., Edgemond, W. S., Jarrahian, A., & Campbell, W. B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69020631.x · Cited by 338
Synergistic interactions between cannabinoid and opioid analgesics
Cichewicz, D. L. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.038 · Cited by 305 · cited 1×
“The first approach is through the exploitation of synergistic analgesic effects of CB 1 and μ- or δ- opioid-receptor agonists, which, through the co-administration (for example, of THC and morphine), produces analgesic actions stronger and longer-lasting (through the avoidance of the development of morphine tolerance)…”
di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1432 · Cited by 303
Self-citationFatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system
Cravatt, B. F., & Lichtman, A. H. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00079-6 · Cited by 302
Lichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301 · cited 1×
“The importance of endocannabinoid inactivation mechanisms is underlined by a number of observations: low pain sensitivity and low susceptibility to developing colon inflammatio”
Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., & Kunos, G. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00631.x · Cited by 296
Self-citationTargeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S., & Nagarkatti, M. (2002) · Blood · doi:10.1182/blood-2002-01-0098 · Cited by 288
Possible endocannabinoid control of colorectal cancer growth
Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M. G., Cosenza, V., D’argenio, G., Scaglione, G., Bifulco, M., Sorrentini, I., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00881-3 · Cited by 287
Self-citationActivation of peripheral CB1 cannabinoid receptors in haemorrhagic shock
Wagner, J. A., Varga, K., Ellis, E. F., Rzigalinski, B. A., Martin, B. R., & Kunos, G. (1997) · Nature · doi:10.1038/37371 · Cited by 284
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283
Evidence against the presence of an anandamide transporter
Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M., & Deutsch, D. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730816100 · Cited by 279
BISOGNO, T., SEPE, N., MELCK, D., MAURELLI, S., PETROCELLIS, L. D., & MARZO, V. D. (1997) · Biochemical Journal · doi:10.1042/bj3220671 · Cited by 275
Self-citationMuller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Izzo, A. A., Fezza, F., Capasso, R., Bisogno, T., Pinto, L., Iuvone, T., Esposito, G., Mascolo, N., Di Marzo, V., & Capasso, F. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704293 · Cited by 256
Self-citationCannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
Mechoulam, R., & Hanuš, L. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00144-5 · Cited by 250
Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A., & Bisogno, T. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0349 · Cited by 242
Self-citationRelation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage
Maccarrone, M., Valensise, H., Bari, M., Lazzarin, N., Romanini, C., & Finazzi-Agrò, A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02115-2 · Cited by 241
Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., Benowitz, N. L., Bredt, B. M., Kosel, B., Aberg, J. A., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00008 · Cited by 238
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret
Van Sickle, M. D., Oland, L. D., Ho, W., Hillard, C. J., Mackie, K., Davison, J. S., & Sharkey, K. A. (2001) · Gastroenterology · doi:10.1053/gast.2001.28466 · Cited by 233
Schmid, P. C., Reddy, P. V., Natarajan, V, & Schmid, H. H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44667-9 · Cited by 232
The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response
Williams, E.-J., Walsh, F. S., & Doherty, P. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200210164 · Cited by 230
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230
Loss of cannabinoid receptors in the substantia nigra in huntington's disease
Glass, M., Faull, R. L. M., & Dragunow, M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90352-g · Cited by 230
Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice
Parmentier-Batteur, S., Jin, K., Mao, X. O., Xie, L., & Greenberg, D. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09771.2002 · Cited by 225
Sugiura, T., Kondo, S., Sukagawa, A., Tonegawa, T., Nakane, S., Yamashita, A., Ishima, Y., & Waku, K. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0053h.x · Cited by 211
Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., & Brenneisen, R. (2003) · Pain · doi:10.1016/s0304-3959(03)00163-5 · Cited by 209
Cellular accumulation of anandamide: consensus and controversy
Hillard, C. J., & Jarrahian, A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705468 · Cited by 203
Discovery and characterization of endogenous cannabinoids
Martin, B. R., Mechoulam, R., & Razdan, R. K. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00281-7 · Cited by 202
Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T., & Inaba, T. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38760-9 · Cited by 200
Di MARZO, V., De PETROCELLIS, L., SEPE, N., & BUONO, A. (1996) · Biochemical Journal · doi:10.1042/bj3160977 · Cited by 196
Self-citationCannabis, cannabinoids and reproduction
Park, B., McPartland, J. M., & Glass, M. (2004) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.04.007 · Cited by 192
Clement, A. B., Hawkins, E. G., Lichtman, A. H., & Cravatt, B. F. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03916.2003 · Cited by 188
Melck, D., Bisogno, T., De Petrocellis, L., Chuang, H.-H., Julius, D., Bifulco, M., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1105 · Cited by 188
Self-citationLack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain
Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., & Rowbotham, D. J. (2003) · Pain · doi:10.1016/s0304-3959(03)00331-2 · Cited by 184
Portella, G., Laezza, C., Laccetti, P., De Petrocellis, L., Di Marzo, V., & Bifulco, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-1129fje · Cited by 184
Self-citationNonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.
Feigenbaum, J. J., Bergmann, F., Richmond, S. A., Mechoulam, R., Nadler, V, Kloog, Y., & Sokolovsky, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9584 · Cited by 183
Endocannabinoids as physiological regulators of colonic propulsion in mice
Pinto, L., Izzo, A. A., Mascolo, N., Capasso, F., Cascio, M. G., Bisogno, T., Di Marzo, V., Hospodar–Scott, K., & Brown, D. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.34242 · Cited by 180
Self-citationMaccarrone, M. (2002) · Molecular Human Reproduction · doi:10.1093/molehr/8.2.188 · Cited by 179
Self-citationArachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide Hydrolase
Bisogno, T., Melck, D., De Petrocellis, L., Bobrov, M. Y., Gretskaya, N. M., Bezuglov, V. V., Sitachitta, N., Gerwick, W. H., & Marzo, V. D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8874 · Cited by 173
Self-citationAnandamide, an endogenous cannabinomimetic eicosanoid: ‘Killing two birds with one stone’
Di Marzo, V., & Fontana, A. (1995) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/0952-3278(95)90077-2 · Cited by 170
Self-citationDenovan-Wright, E. M., & Robertson, H. A. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00157-3 · Cited by 169
Established and potential therapeutic applications of cannabinoids in oncology
Walsh, D., Nelson, K. A., & Mahmoud, F. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0387-7 · Cited by 163
Knoller, N., Levi, L., Shoshan, I., Reichenthal, E., Razon, N., Rappaport, Z. H., & Biegon, A. (2002) · Critical Care Medicine · doi:10.1097/00003246-200203000-00009 · Cited by 162
Cannabinoids: a real prospect for pain relief
Iversen, L. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00120-5 · Cited by 162
Guzmán, M., Sánchez, C., & Galve-Roperh, I. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00256-5 · Cited by 161
CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids
McAllister, S. D., & Glass, M. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0344 · Cited by 159
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation
Bifulco, M., Laezza, C., Valenti, M., Ligresti, A., Portella, G., & Marzo, V. D. (2004) · The FASEB Journal · doi:10.1096/fj.04-1754fje · Cited by 157
Self-citationPorcella, A., Maxia, C., Gessa, G. L., & Pani, L. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2000.01401.x · Cited by 154
Wang, H., Matsumoto, H., Guo, Y. X., Paria, B. C., Roberts, R. L., & Dey, S. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436379100 · Cited by 152
Further evidence for the existence of a specific process for the membrane transport of anandamide
Ligresti, A., Morera, E., van der Stelt, M., Monory, K., Lutz, B., Ortar, G., & Marzo, V. D. (2004) · Biochemical Journal · doi:10.1042/bj20031812 · Cited by 149
Self-citationEndogenous cannabinoids mediate hypotension after experimental myocardial infarction
Wagner, J. A., Hu, K., Bauersachs, J. K., Karcher, J. C., Wiesler, M., Goparaju, S. K., Kunos, G., & Ertl, G. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01671-0 · Cited by 148
Novel selective and metabolically stable inhibitors of anandamide cellular uptake
Ortar, G., Ligresti, A., PETROCELLIS, L. D., Morera, E., & Marzo, V. D. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00109-6 · Cited by 148
Self-citationCannabinoids for gastrointestinal diseases: potential therapeutic applications
Carlo, G. D., & Izzo, A. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.39 · Cited by 146
Cardiovascular effects of cannabinoids
Randall, M. D., Harris, D., Kendall, D. A., & Ralevic, V. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00258-9 · Cited by 145
Darmani, N. N. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00197-4 · Cited by 145
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism
Maccarrone, M., Gubellini, P., Bari, M., Picconi, B., Battista, N., Centonze, D., Bernardi, G., Finazzi‐Agrò, A., & Calabresi, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01759.x · Cited by 143
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice
Izzo, A. A., Capasso, F., Costagliola, A., Bisogno, T., Marsicano, G., Ligresti, A., Matias, I., Capasso, R., Pinto, L., Borrelli, F., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00892-8 · Cited by 140
Self-citationControl by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth
Bifulco, M., Laezza, C., Portella, G., Vitale, M., Orlando, P., PETROCELLIS, L. D., & Marzo, V. D. (2001) · The FASEB Journal · doi:10.1096/fj.01-0320fje · Cited by 140
Self-citationMarzo, V. D., Bisogno, T., PETROCELLIS, L. D., Brandi, I., Jefferson, R. G., Winckler, R., Davis, J. B., DASSE, O. A., Mahadevan, A., Razdan, R. K., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4354 · Cited by 138
Self-citationSumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R., & Feldmann, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20050 · Cited by 134
Liu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade
Mazzola, C., Micale, V., & Drago, F. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.026 · Cited by 122
Fox, S. H., Kellett, M., Moore, A. P., Crossman, A. R., & Brotchie, J. M. (2002) · Movement Disorders · doi:10.1002/mds.1280 · Cited by 120
Release of Fatty Acid Amides in a Patient With Hemispheric Stroke: A Microdialysis Study
Schäbitz, W.-R., Giuffrida, A., Berger, C., Aschoff, A. A., Schwaninger, M., Schwab, S., & Piomelli, D. (2002) · Stroke · doi:10.1161/01.str.0000023491.63693.18 · Cited by 118
Pharmacology of Cannabinoid CB 1 and CB 2 Receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · Cited by 112
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease
Lastres‐Becker, I., Fezza, F., Cebeira, M., Bisogno, T., Ramos, J. A., Milone, A., Fernández‐Ruíz, J., & Marzo, V. D. (2001) · Neuroreport · doi:10.1097/00001756-200107200-00017 · Cited by 99
Self-citationThe endocannabinoid system and the molecular basis of paralytic ileus in mice
Mascolo, N., Izzo, A. A., Ligresti, A., Costagliola, A., Pinto, L., Cascio, M. G., Maffia, P., Cecio, A., Capasso, F., & Marzo, V. D. (2002) · The FASEB Journal · doi:10.1096/fj.02-0338fje · Cited by 99
Self-citationAlberich-Jordà, M., Rayman, N., Tas, M., Verbakel, S. E., Battista, N., van Lom, K., Löwenberg, B., Maccarrone, M., & Delwel, R. (2004) · Blood · doi:10.1182/blood-2003-12-4357 · Cited by 89
Brooks, J. W., Pryce, G., Bisogno, T., Jaggar, S., Hankey, D. J. R., Brown, P., Bridges, D., Ledent, C. A., Bifulco, M., Rice, A. S. C., et al. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01369-9 · Cited by 85
Self-citationSilverdale, M., McGuire, S., McInnes, A., Crossman, A. R., & Brotchie, J. M. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7649 · Cited by 83
Oral morphine and respiratory function amongst hospice inpatients with advanced cancer
Walsh, D., Rivera, N. I., & Kaiko, R. F. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0530-0 · Cited by 83
López-Rodríguez, M. L., Viso, A., Ortega‐Gutiérrez, S., Fowler, C. J., Tiger, G., de Lago, E., Fernández‐Ruíz, J., & Ramos, J. A. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0210818 · Cited by 82
Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide
Marzo, V. D., Breivogel, C. S., Bisogno, T., Melck, D. J., Patrick, G., Tao, Q., SZALLASI, A., Razdan, R. K., & Martin, B. R. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00687-7 · Cited by 80
Self-citationBerrendero, F., Sánchez, A., Cabranes, A., Puerta, C., Ramos, J. A., García‐Merino, A., & Fernández‐Ruíz, J. (2001) · Synapse · doi:10.1002/syn.1075 · Cited by 77
Anandamide and other N‐acylethanolamines in human tumors
Schmid, P. C., Wold, L. E., Krebsbach, R. J., Berdyshev, E. V., & Schmid, H. H. O. (2002) · Lipids · doi:10.1007/s11745-002-0978-z · Cited by 77
The role of endocannabinoids in the hypothalamic regulation of visceral function
Wenger, T., & Moldrich, G. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0353 · Cited by 76
O‐1057, a potent water‐soluble cannabinoid receptor agonist with antinociceptive properties
Pertwee, R. G., Gibson, T. M., Stevenson, L., Ross, R. A., Banner, W. K., Saha, B., Razdan, R. K., & Martin, B. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703245 · Cited by 75
Analysis of the respiratory effects of cannabinoids in rats
Schmid, K., Niederhoffer, N., & Szabó, B. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0787-3 · Cited by 65
De Vry, J., Denzer, D., Reissmueller, E., Eijckenboom, M., Heil, M., Meier, H., & Mauler, F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062836 · Cited by 63
Cannabinoid Properties of Methylfluorophosphonate Analogs
Martin, B. R., Beletskaya, I., Patrick, G., Jefferson, R. G., Winckler, R., Deutsch, D. G., Marzo, V. D., Dasse, O. A., Mahadevan, A., & Razdan, R. K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39191-8 · Cited by 46
Self-citationAjulemic Acid (CT3) A Potent Analog of the Acid Metabolites of THC
BURSTEIN, S. H. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399473 · Cited by 40
Mauler, F., Horváth, E., Vry, J. D., Jäger, R., Schwarz, T., Sandmann, S., Weinz, C., Heinig, R., & Böttcher, M. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00259.x · Cited by 34
Cannabis-Based Medicines ??? GW Pharmaceuticals
&NA; (2003) · Drugs in R&D · doi:10.2165/00126839-200304050-00005 · Cited by 30
Wiley, J. L., Jefferson, R. G., Griffin, G., Liddle, J., Yu, S., Huffman, J. W., & Martin, B. R. (2002) · Pharmacology · doi:10.1159/000065631 · Cited by 17
Marijuana safety study completed: weight gain, no safety problems.
Js, J. (2000) · PubMed · Cited by 12
Is cannabinoid transmission involved in rewarding properties of drugs of abuse?
Parolaro, D., & Rubino, T. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704826 · Cited by 5
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…marijuana and the recent resurgence of interest in its medicinal properties have been the subject of excellent reviews (Mechoulam, 1986; Iversen, 2000; Di Marzo et al., 2004; Howlett et al., 2004; Pertwee, 2005a; Piomelli, 2005; Di Marzo and Petrocellis, 2006; Mackie, 2006; Pagotto et al., 2006).”
BackgroundVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Self-citationEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.